Michael Stahl

Paclitaxel and carboplatin vs gemcitabine and vinorelbine in patients with adeno- or undifferentiated carcinoma of unknown primary: a randomised prospective phase II trial

G. Huebner, Hartmut Link, C.-H. Köhne et al. · British Journal of Cancer · 2008 · 87 citations · Full text

Medicine, Oncology, Pharmacology +12

Randomised phase II trial to investigate catumaxomab (anti-EpCAM × anti-CD3) for treatment of peritoneal carcinomatosis in patients with gastric cancer

Maren Knödler, Justus Körfer, Volker Kunzmann et al. · British Journal of Cancer · 2018 · 85 citations · Full text

Medicine, Oncology, Pharmacology +14

Molecularly guided therapy versus chemotherapy after disease control in unfavourable cancer of unknown primary (CUPISCO): an open-label, randomised, phase 2 study

Alwin Krämer, Tilmann Bochtler, Chantal Pauli et al. · The Lancet · 2024 · 75 citations · Full text

Medicine, Clinical Sciences, Oncology +8

FOLFIRI plus ramucirumab versus paclitaxel plus ramucirumab as second-line therapy for patients with advanced or metastatic gastroesophageal adenocarcinoma with or without prior docetaxel – results from the phase II RAMIRIS Study of the German Gastric Cancer Study Group at AIO

Sylvie Lorenzen, Peter Thuss‐Patience, Claudia Pauligk et al. · European Journal of Cancer · 2022 · 56 citations

Medicine, Oncology, Pharmacotherapy +14

Paclitaxel/carboplatin with or without belinostat as empiric first‐line treatment for patients with carcinoma of unknown primary site: A randomized, phase 2 trial

John D. Hainsworth, Gedske Daugaard, Thierry Lesimple et al. · Cancer · 2015 · 48 citations · Full text

Medicine, Oncology, Pharmacology +11